Principal Financial Group Inc. Grows Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Principal Financial Group Inc. grew its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 10.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 113,217 shares of the company’s stock after acquiring an additional 10,748 shares during the quarter. Principal Financial Group Inc. owned about 0.08% of Xeris Biopharma worth $384,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Xeris Biopharma during the 3rd quarter worth approximately $35,000. R Squared Ltd purchased a new position in shares of Xeris Biopharma during the 4th quarter valued at approximately $42,000. Quantbot Technologies LP purchased a new position in shares of Xeris Biopharma during the 3rd quarter valued at approximately $44,000. Janney Montgomery Scott LLC lifted its stake in Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after purchasing an additional 5,500 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Xeris Biopharma by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock worth $107,000 after purchasing an additional 2,954 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

XERS opened at $4.24 on Friday. The business has a 50-day moving average of $3.55 and a 200-day moving average of $3.24. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.69 and a fifty-two week high of $4.50. The company has a market capitalization of $632.10 million, a PE ratio of -9.42 and a beta of 2.32.

Wall Street Analyst Weigh In

XERS has been the topic of several analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research report on Friday.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.